Literature DB >> 26218756

Serum 8-isoprostane levels and paraoxonase 1 activity in patients with stage I multiple myeloma.

Yousef Faridvand1, Ali Eishi Oskuyi2, Mohammad-Hassan Khadem-Ansari1.   

Abstract

OBJECTIVE: Multiple myeloma (MM) is a plasma cell malignancy comprising 15% of hematological malignancies. Many studies have assessed the relationship between free radicals and tumor progression or cancer risk. We aimed to evaluate the antioxidant activity of paraoxonase 1 (PON1), arylesterase (ARE), and 8-isoprostane in patients with stage I MM.
MATERIALS AND METHODS: Spectrophotometric assays of serum PON1 and ARE activities in addition to serum 8-isoprostane level were performed in 34 patients newly diagnosed with stage I MM as compared to 35 age- and sex-matched individuals who comprised the healthy control group.
RESULTS: A significant reduction was found in the activities of PON1 and ARE (for both, P < 0.001) in the patient group. The ratio of PON1/high-density lipoprotein was significantly lower in the MM patient group than in the control group (P < 0.001), while 8-isoprostane levels compared with the control group were significantly higher (P < 0.001), observations that may indicate an increase in oxidative stress in stage I MM patients.
CONCLUSION: A decrease in PON1 activity and increase in 8-isoprostane serum activities in patients may indicate the importance of lipid peroxidation in MM disease. Oxidative stress and especially lipid peroxidation could reduce the antioxidant activity of PON1 and ARE in MM patients and could be considered as factors in the pathogenesis of MM disease.

Entities:  

Keywords:  8-isoprostane; Multiple myeloma; Oxidative stress; Paraoxonase 1

Mesh:

Substances:

Year:  2016        PMID: 26218756      PMCID: PMC6837499          DOI: 10.1179/1351000215Y.0000000034

Source DB:  PubMed          Journal:  Redox Rep        ISSN: 1351-0002            Impact factor:   4.412


  29 in total

Review 1.  Cancer-associated malnutrition: an introduction.

Authors:  Maarten von Meyenfeldt
Journal:  Eur J Oncol Nurs       Date:  2005       Impact factor: 2.398

Review 2.  The codependence of angiogenesis and chronic inflammation.

Authors:  J R Jackson; M P Seed; C H Kircher; D A Willoughby; J D Winkler
Journal:  FASEB J       Date:  1997-05       Impact factor: 5.191

3.  A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism.

Authors:  J D Morrow; K E Hill; R F Burk; T M Nammour; K F Badr; L J Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

Review 4.  Isoprostanes: markers and mediators of oxidative stress.

Authors:  Paolo Montuschi; Peter J Barnes; L Jackson Roberts
Journal:  FASEB J       Date:  2004-12       Impact factor: 5.191

5.  Oxidant-antioxidant status alterations in cancer patients: relationship to tumor progression.

Authors:  M Gerber; C Astre; C Ségala; M Saintot; J Scali; J Simony-Lafontaine; J Grenier; H Pujol
Journal:  J Nutr       Date:  1996-04       Impact factor: 4.798

6.  Antioxidant enzymes and lipid peroxidation in patients with multiple myeloma.

Authors:  T Zima; I Spicka; S Stípek; J Crkovská; J Pláteník; M Merta; V Tesar
Journal:  Neoplasma       Date:  1996       Impact factor: 2.575

7.  VEGF, TNF-alpha and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer.

Authors:  Eleftherios Dalaveris; Theodora Kerenidi; Alexandra Katsabeki-Katsafli; Theodoros Kiropoulos; Kalliopi Tanou; Konstantinos I Gourgoulianis; Konstantinos Kostikas
Journal:  Lung Cancer       Date:  2008-10-09       Impact factor: 5.705

8.  Serum paraoxonase-1 enzyme activities and oxidative stress levels in patients with esophageal squamous cell carcinoma.

Authors:  Abidin Sehitogulları; Mehmet Aslan; Fuat Sayır; Ali Kahraman; Halit Demir
Journal:  Redox Rep       Date:  2014-04-14       Impact factor: 4.412

9.  Elevated levels of urinary 8-hydroxy-2'-deoxyguanosine and 8-isoprostane in esophageal squamous cell carcinoma.

Authors:  Mohammad-Hassan Khadem-Ansari; Zahra Shahsavari; Yousef Rasmi; Rahim Mahmoodlo
Journal:  J Carcinog       Date:  2011-04-16

10.  Multiple myeloma: relationship to antioxidant esterases.

Authors:  Hamit Yasar Ellidag; Esin Eren; Ozgur Aydin; Mustafa Yıldırım; Cem Sezer; Necat Yilmaz
Journal:  Med Princ Pract       Date:  2013-11-05       Impact factor: 1.927

View more
  6 in total

Review 1.  The Relationship between Cancer and Paraoxonase 1.

Authors:  Irma Martha Medina-Díaz; Néstor Ponce-Ruíz; Aurora Elizabeth Rojas-García; José Francisco Zambrano-Zargoza; Yael Y Bernal-Hernández; Cyndia Azucena González-Arias; Briscia S Barrón-Vivanco; José Francisco Herrera-Moreno
Journal:  Antioxidants (Basel)       Date:  2022-03-31

Review 2.  Oxidative stress and proteasome inhibitors in multiple myeloma.

Authors:  Brittany C Lipchick; Emily E Fink; Mikhail A Nikiforov
Journal:  Pharmacol Res       Date:  2016-01-29       Impact factor: 7.658

3.  Classifying oxidative stress by F2-isoprostane levels across human diseases: A meta-analysis.

Authors:  Thomas J van 't Erve; Maria B Kadiiska; Stephanie J London; Ronald P Mason
Journal:  Redox Biol       Date:  2017-03-28       Impact factor: 11.799

4.  Association between Paraoxonase 1 polymorphisms and risk of esophagogastric junction adenocarcinoma: a case-control study involving 2,740 subjects.

Authors:  Weifeng Tang; Jianchao Liu; Yafeng Wang; Yanchao Chen; Mingqiang Kang; Jun Yin; Chao Liu; Jing Lin; Yu Chen
Journal:  Oncotarget       Date:  2017-08-10

5.  Serum Levels of Interleukin-8 and Soluble Interleukin-6 Receptor in Patients with Stage-I Multiple Myeloma: A Case-Control Study.

Authors:  Maryam Kohsari; Mohammad-Hassan Khadem-Ansari; Yousef Rasmi; Hojjat Sayyadi
Journal:  Asian Pac J Cancer Prev       Date:  2020-01-01

Review 6.  Modulation of Cellular Redox Parameters for Improving Therapeutic Responses in Multiple Myeloma.

Authors:  Alessandro Allegra; Claudia Petrarca; Mario Di Gioacchino; Marco Casciaro; Caterina Musolino; Sebastiano Gangemi
Journal:  Antioxidants (Basel)       Date:  2022-02-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.